Oncology/Hematology
Renal Cell Carcinoma
More in Renal Cell Carcinoma
Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC
Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease
Better OS, PFS, response rate, but newer combination strategies not included
More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery
Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions
Confirmed responses in one-fourth to one-third of patients with refractory disease
Data support that ICI rechallenge should be discouraged in patients with advanced RCC
News, features, and commentary about cancer-related issues
Similar outcomes with immediate versus delayed surgery, supporting use of active surveillance
Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS
Occurs most often at non-academic and low-volume centers
HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF
Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance
Potential standard of care after current therapies, but key obstacles remain in the way
